273 related articles for article (PubMed ID: 30049387)
1. Cytokine Networks and Survivin Peptide-Specific Cellular Immune Responses Predict Improved Survival in Patients With Glioblastoma Multiforme.
Zhenjiang L; Rao M; Luo X; Valentini D; von Landenberg A; Meng Q; Sinclair G; Hoffmann N; Karbach J; Altmannsberger HM; Jäger E; Peredo IH; Dodoo E; Maeurer M
EBioMedicine; 2018 Jul; 33():49-56. PubMed ID: 30049387
[TBL] [Abstract][Full Text] [Related]
2. Mesothelin-specific Immune Responses Predict Survival of Patients With Brain Metastasis.
Zhenjiang L; Rao M; Luo X; Sandberg E; Bartek J; Schoutrop E; von Landenberg A; Meng Q; Valentini D; Poiret T; Sinclair G; Peredo IH; Dodoo E; Maeurer M
EBioMedicine; 2017 Sep; 23():20-24. PubMed ID: 28888924
[TBL] [Abstract][Full Text] [Related]
3. NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma.
Liu Z; Poiret T; Persson O; Meng Q; Rane L; Bartek J; Karbach J; Altmannsberger HM; Illies C; Luo X; Harvey-Peredo I; Jäger E; Dodoo E; Maeurer M
Cancer Immunol Immunother; 2018 Feb; 67(2):237-246. PubMed ID: 29058035
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.
Inogés S; Tejada S; de Cerio AL; Gállego Pérez-Larraya J; Espinós J; Idoate MA; Domínguez PD; de Eulate RG; Aristu J; Bendandi M; Pastor F; Alonso M; Andreu E; Cardoso FP; Valle RD
J Transl Med; 2017 May; 15(1):104. PubMed ID: 28499389
[TBL] [Abstract][Full Text] [Related]
5. Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.
Erhart F; Buchroithner J; Reitermaier R; Fischhuber K; Klingenbrunner S; Sloma I; Hibsh D; Kozol R; Efroni S; Ricken G; Wöhrer A; Haberler C; Hainfellner J; Krumpl G; Felzmann T; Dohnal AM; Marosi C; Visus C
Acta Neuropathol Commun; 2018 Dec; 6(1):135. PubMed ID: 30518425
[TBL] [Abstract][Full Text] [Related]
6. Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.
Kozlowska AK; Tseng HC; Kaur K; Topchyan P; Inagaki A; Bui VT; Kasahara N; Cacalano N; Jewett A
Cancer Immunol Immunother; 2016 Sep; 65(9):1085-97. PubMed ID: 27439500
[TBL] [Abstract][Full Text] [Related]
7. Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial.
Yao Y; Luo F; Tang C; Chen D; Qin Z; Hua W; Xu M; Zhong P; Yu S; Chen D; Ding X; Zhang Y; Zheng X; Yang J; Qian J; Deng Y; Hoon DSB; Hu J; Chu Y; Zhou L
Cancer Immunol Immunother; 2018 Nov; 67(11):1777-1788. PubMed ID: 30159779
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of interferon-gamma, interleukin-6, and tumor necrosis factor-alpha in the radiation response of patients diagnosed with locally advanced non-small-cell lung cancer and glioblastoma multiforme.
Deniz ÇD; Gürbilek M; Koç M
Turk J Med Sci; 2018 Feb; 48(1):117-123. PubMed ID: 29479968
[TBL] [Abstract][Full Text] [Related]
9. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
Tang J; Flomenberg P; Harshyne L; Kenyon L; Andrews DW
Clin Cancer Res; 2005 Jul; 11(14):5292-9. PubMed ID: 16033848
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme.
Crough T; Beagley L; Smith C; Jones L; Walker DG; Khanna R
Immunol Cell Biol; 2012 Oct; 90(9):872-80. PubMed ID: 22508289
[TBL] [Abstract][Full Text] [Related]
11. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma.
Wang ZQ; Zhang MY; Deng ML; Weng NQ; Wang HY; Wu SX
PLoS One; 2017; 12(9):e0184969. PubMed ID: 28931080
[TBL] [Abstract][Full Text] [Related]
12. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.
Liu G; Ying H; Zeng G; Wheeler CJ; Black KL; Yu JS
Cancer Res; 2004 Jul; 64(14):4980-6. PubMed ID: 15256472
[TBL] [Abstract][Full Text] [Related]
13. PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme.
Struss AK; Romeike BF; Munnia A; Nastainczyk W; Steudel WI; König J; Ohgaki H; Feiden W; Fischer U; Meese E
Oncogene; 2001 Jul; 20(31):4107-14. PubMed ID: 11464277
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM).
Grunda JM; Nabors LB; Palmer CA; Chhieng DC; Steg A; Mikkelsen T; Diasio RB; Zhang K; Allison D; Grizzle WE; Wang W; Gillespie GY; Johnson MR
J Neurooncol; 2006 Dec; 80(3):261-74. PubMed ID: 16773218
[TBL] [Abstract][Full Text] [Related]
15. Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma.
Liu Z; Rao M; Poiret T; Nava S; Meng Q; von Landenberg A; Bartek J; Xie S; Sinclair G; Peredo I; Dodoo E; Maeurer M
Oncotarget; 2017 Oct; 8(46):80208-80222. PubMed ID: 29113296
[TBL] [Abstract][Full Text] [Related]
16. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions.
Avril T; Saikali S; Vauleon E; Jary A; Hamlat A; De Tayrac M; Mosser J; Quillien V
J Neuroimmunol; 2010 Aug; 225(1-2):22-33. PubMed ID: 20493562
[TBL] [Abstract][Full Text] [Related]
17. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients.
Wheeler CJ; Black KL; Liu G; Mazer M; Zhang XX; Pepkowitz S; Goldfinger D; Ng H; Irvin D; Yu JS
Cancer Res; 2008 Jul; 68(14):5955-64. PubMed ID: 18632651
[TBL] [Abstract][Full Text] [Related]
18. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis.
Sreekanthreddy P; Srinivasan H; Kumar DM; Nijaguna MB; Sridevi S; Vrinda M; Arivazhagan A; Balasubramaniam A; Hegde AS; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1409-22. PubMed ID: 20530493
[TBL] [Abstract][Full Text] [Related]
19. Preoperative biomarkers of tumour vascularity are elevated in patients with glioblastoma multiforme.
Bennett IE; Guo H; Kountouri N; D'abaco GM; Hovens CM; Moffat BA; Desmond P; Drummond K; Kaye AH; Morokoff AP
J Clin Neurosci; 2015 Nov; 22(11):1802-8. PubMed ID: 26308396
[TBL] [Abstract][Full Text] [Related]
20. Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy.
Saikali S; Avril T; Collet B; Hamlat A; Bansard JY; Drenou B; Guegan Y; Quillien V
J Neurooncol; 2007 Jan; 81(2):139-48. PubMed ID: 17004103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
